A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)

Study Title
A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)
Teva Identifier
TV48574-IMM-20036
ClinicalTrials.gov Identifier
NCT05499130
Study Status
Completed
Trial Condition(s)
Crohn Disease|Colitis, Ulcerative
Interventions
Drug: TEV-48574 | Drug: Placebo
EudraCT Number
2021-006881-19
EU CT Number
2024-511089-36-00
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
inflammation-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 75 Years
Trial Duration
September 30, 2022 - November 12, 2024
Phase
Phase 2

Additional info

Study Type

Interventional